Nurturing Innovation: LaNova Secures $42 Million in Series C Funding from Novartis

LaNova is thrilled to announce that it has successfully raised $42 million in its latest funding round, a significant milestone that underscores the growing confidence and support for our vision of reimaging medicine. As a cutting-edge pharmaceutical company dedicated to developing innovative medicines, LaNova is committed to improving and extending the lives of patients around the globe. With our recent funding, we aim to accelerate the development of groundbreaking therapies targeted at serious diseases that currently lack effective treatment options. The funds will enable us to advance our promising pipeline of drugs through clinical trials, enhance our research capabilities, and boost our operational capacities to ensure that we can reach more patients in need. Currently, our medicines benefit over 250 million people worldwide, and this new influx of capital will help us expand that reach even further. We are incredibly grateful to our investors for their confidence in our mission and our dedicated team, who work tirelessly every day to empower patients, healthcare professionals, and society at large. Together, we are paving the way for a healthier future, one innovative solution at a time. For more information on our initiatives and to stay updated on our progress, visit us at [Novartis.com](https://www.novartis.com).